<DOC>
	<DOCNO>NCT01006980</DOCNO>
	<brief_summary>This randomize , open-label study evaluate efficacy , safety tolerability vemurafenib ( RO5185426 ) compare dacarbazine previously untreated patient metastatic melanoma . Patients randomize receive either vemurafenib 960 mg orally twice daily dacarbazine 1000 mg/m2 intravenously every 3 week . Study treatment continue disease progression unacceptable toxicity occur . The data safety monitor board recommend patient dacarbazine group allow cross receive vemurafenib , protocol amend accordingly January 14 , 2011 , overall survival progression-free survival endpoint meet prespecified criterion statistical significance favor vemurafenib .</brief_summary>
	<brief_title>A Study Vemurafenib ( RO5185426 ) Comparison With Dacarbazine Previously Untreated Patients With Metastatic Melanoma ( BRIM 3 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>adult , &gt; /=18 year age metastatic melanoma , stage IIIC IV ( AJCC ) treatmentna√Øve ( prior systemic anticancer therapy ) positive BRAF V600E mutation measurable disease RECIST criterion negative pregnancy test , fertile men woman , effective contraception treatment 6 month completion active central nervous system metastases history carcinomatous meningitis severe cardiovascular disease within 6 month prior study drug administration previous malignancy within 5 year prior study , except basal squamous cell carcinoma skin , melanoma insitu , carcinoma insitu cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>